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Hungary (e-mail: bene.judit@pte.hu).
This work was supported by OTKA 73430, ETT 210-07/2009 and ÁOKKA
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Objective: The aim of the study was to compare plasma carnitine profiles in
fortified human milk (HM)–fed preterm infants or formula-fed preterm
infants.
Methods: Plasma acylcarnitine concentrations were determined in 20
formula-fed and 18 HM-fed preterm infants (birth weights between 1000
and 2200 g) by isotope dilution ESI MS/MS technique on study days 0, 14,
and 28.
Results: Concentrations of free carnitine (FC) and different acylcarnitines did
not change during the 4 weeks of the study in infants fed HM. In contrast, in
infants fed formula FC increased markedly (day 0: 29.989 [16.646] mmol/L,
median [interquartile range], day 14: 43.972 [8.455], P< 0.05) along with
increases of short-chain esters (C2 day 0: 5.300 [3.272], day 14: 6.773 [2.127],
P< 0.05; C3 day 0: 0.070 [0.059], day 14: 0.110 [0.069], P< 0.05). In
contrast, some medium-chain (C8:1, C12) and long-chain esters (C14,
C16) decreased significantly in infant formula by day 14, whereas FC and
C2 and C3 esters increased further by day 28 (FC: 47.672 [14.753], C2: 7.430
[4.688], C3: 0.107 [0.047]).
Conclusions: The altered carnitine ester profile likely reflects active
involvement of the carnitine molecule in the buffering, metabolism, and
elimination of nonphysiological acyl moieties.Key Words: carnitine ester profile, human milk, mass spectrometry,
premature infant, preterm infant formula
(JPGN 2013;57: 673–676)B efore birth, amino acids and glucose are the main substratesfor fetal metabolism. The human placenta is also permeable to
small amounts of triglycerides, fatty acids, glycerol, and keto acids.
A few hours after delivery, the neonate must switch from glucose
use to oxidation of fat, which becomes the major source of energy
(1,2).
Carnitine, which is present in the body in free and esterified
form (acylcarnitines [ACs]), plays an indispensible role in the
energy metabolism by controlling the influx of long-chain fatty
acids into the mitochondrial matrix where they undergo b-oxidation
(3,4). The fetus probably obtains exogenous carnitine via placental
transport. Carnitine is stored in fetal tissues in increasing amounts
during the third trimester of pregnancy, and tissue stores at birth are
directly related to gestational age (5–10); thus, preterm infants are
born with limited carnitine reserves (11). Because endogenous
synthesis of carnitine is limited in the neonate, preterm infants
cannot achieve carnitine homeostasis without its exogenous supply
(12).
The amount of circulating carnitine as well as carnitine esters
in preterm infants depends on the nutritional status. Different ways
of infant feeding may influence the use of carnitine through either
fat or the amino acid content of the nutrients. We investigated
carnitine levels longitudinally by using mass spectrometry (MS) in
preterm neonates fed human milk (HM) or infant formula (IF)
during the period of 28 days to assess the effect of way of feeding on
carnitine homeostasis.
METHODS
Subjects and Sample Collection
We studied samples of 38 preterm infants (20 formula-fed
and 18 human milk-fed) with birth weights between 1000 and
2200 g who had participated in a previously reported feeding trial
(13). Briefly, participating infants were recruited from the neo-
natal units of 5 German hospitals and included in the study within
the first 14 days of life (postnatal age was 13 1 days for
formula-fed, and 12 3 days for human milk–fed infants) after
full enteral feeding was established (>80 mL  kg1 day1) and at
least 80% of the caloric intake was derived from either human
milk or preterm formula (based on Beba preterm infant formula,
Nestlé Nutrition, Frankfurt, Germany), which contained 1.7 mg
carnitine and 4.16 g fat in 100 mL standard solution (13). Human
milk was fortified with FM 85 (Nestlé Nutrition) that contained
no carnitine. Before study entry, infants were fed according to
hospital routine.
Infants with severe malformations, apparent genetic, gastro-duction of this article is prohibited.
disorders, artificial ventilation or oxygen
time of enrollment, and administration of
673
Coparenteral fat emulsion (>1 g  kg1  day1 triglycerides for
>7 days) before study entry were excluded from the study.
Venous blood samples were collected in ethylenediamine-
tetraacetic acid tubes from all infants on study days 0, 14, and 28.
Plasma was separated by centrifugation (5 minutes, 1000g, room
temperature) and stored at 208C until analysis.
Informed consent was obtained from all of the parents before
the study. During the entire study period, the guidelines and
regulations approved by the University of Munich Medical Centre
were followed and the study was carried out in accordance with the
Helsinki Declaration of 1975, as revised in 2000.
MS Analysis
Free carnitine (FC) and all the ACs were determined in butyl-
ester forms using isotope dilution MS method. Flow injection
analysis was applied for the individual measurements, which were
carried out in a Micromass Quattro Ultima ESI (electrospray
Bene et alpyright 2013 by ESPGHAN and NASPGHAN. Un
ionization) triple-quadrupole mass spectrometer coupled with a
Waters 2795 HPLC (Milford, MA) system for sample introduction.









Carnitine esters Median (IQR) Median (IQR) Median (IQ
FC 26.097 (11.347) 29.898 (16.646) 25.633 (10.
Total AC 6.388 (2.428) 6.265 (3.555) 6.971 (2.9
Total carnitine 31.802 (11.902) 36.062 (19.533) 33.043 (12.
AC/FC ratio 0.249 (0.087) 0.189 (0.161) 0.252 (0.0
Total short-chain ACs 5.811 (2.349) 5.579 (3.487) 6.357 (2.6
Total medium-chain AC 0.439 (0.223) 0.497 (0.108) 0.454 (0.2
Total long-chain AC 0.184 (0.055) 0.163 (0.057) 0.189 (0.1
Short-chain AC
C2-carnitine 5.497 (2.477) 5.300 (3.273) 6.097 (2.6
C3-carnitine 0.058 (0.043) 0.070 (0.059) 0.050 (0.0
C4-carnitine 0.063 (0.013) 0.077 (0.014)a 0.056 (0.0
C5-carnitine 0.145 (0.052) 0.153 (0.087) 0.123 (0.0
Medium-chain ACs
C6-carnitine 0.017 (0.00) 0.020 (0.003) 0.017 (0.0
C8-carnitine 0.058 (0.057) 0.087 (0.059) 0.068 (0.0
C8:1-carnitine 0.097 (0.058) 0.133 (0.052) 0.107 (0.0
C10-carnitine 0.073 (0.067) 0.086 (0.045) 0.087 (0.0
C10:1-carnitine 0.060 (0.036) 0.060 (0.029) 0.063 (0.0
C10:2-carnitine 0.030 (0.011) 0.037 (0.016) 0.028 (0.0
C12-carnitine 0.053 (0.020) 0.037 (0.032) 0.055 (0.0
C12:1-carnitine 0.025 (0.013) 0.020 (0.008) 0.028 (0.0
Long-chain ACs
C14-carnitine 0.044 (0.019) 0.040 (0.022) 0.047 (0.0
C14:1-carnitine 0.043 (0.019) 0.040 (0.024) 0.042 (0.0
C14:2-carnitine 0.022 (0.010) 0.026 (0.012) 0.024 (0.0
C16-carnitine 0.050 (0.025) 0.050 (0.023) 0.050 (0.0
C18-carnitine 0.015 (0.013) 0.017 (007) 0.017 (0.0
Different superscript a, b, c indicate significant differences between groups
FC¼ free carnitine; IQR¼ interquartile range.
Significantly different from study day 0 (P< 0.05) (Wilcoxon test).
# Significantly different from study day 14 (P< 0.05) (Wilcoxon test).
674For sample preparation, 10 mL of plasma was used and then a
previously described procedure was followed (14). During the ESI
MS/MS analysis, FC and ACs were measured by positive precursor
ion scan of m/z 85, with a scan range of m/z 200 to 550. The
applied capillary voltage, cone voltage, and collision energy were
2.54 kV, 55 V, and 26 eV, respectively. Our mass spectrometry
facility is registered participant in the International Newborn
Screening Quality Assurance Program organized by the Centers
for Disease Control and Prevention (http://www2.cdc.gov/nceh/
NewbornScreening).
Statistical Analysis
All statistical analyses were performed with SPSS version 20
(SPSS Inc, Chicago, IL). Variables are presented as median and
interquartile range. The effect of diet on plasma carnitine ester
concentration on days 0, 14, and 28 was studied with Mann-
Whitney U tests. Changes in carnitine ester concentrations over
JPGN  Volume 57, Number 5, November 2013authorized reproduction of this article is prohibited.
time within groups (day 0 to day 14 to day 28) were analyzed using
the Friedman test. If changes were found to be significant, Wilcoxon
with HM and with preterm IF in days 0, 14, and 28
Day 14 Day 28






R) Median (IQR) Median (IQR) Median (IQR)
417) 43.972 (8.455)








,b 35.292 (8.567) 55.929 (14.553),#,c
















,b 0.193 (0.034),# 0.141 (0.055),#,c
87) 6.773 (2.127)
,b 6.977 (2.277) 7.430 (4.688),c
31) 0.110 (0.069)
,b 0.082 (0.068) 0.117 (0.047)
16) 0.087 (0.032)b 0.057 (0.023) 0.085 (0.028)c
56) 0.180 (0.033)b 0.125 (0.043) 0.163 (0.066)c
06) 0.017 (0.007) 0.017 (0.003) 0.017 (0.007)
35) 0.097 (0.018)b 0.068 (0.034) 0.103 (0.049)c
42) 0.092 (0.038)

0.107 (0.067) 0.102 (0.045)

35) 0.106 (0.025)b 0.082 (0.053) 0.102 (0.061)
28) 0.052 (0.024) 0.062 (0.024) 0.056 (0.017)
13) 0.026 (0.010) 0.030 (0.016) 0.027 (0.011)
23) 0.020 (0.011)
,b 0.053 (0.016) 0.028 (0.008),c
23) 0.014 (0.008) 0.024 (0.013) 0.015 (0.013)
16) 0.023 (0.010)
,b 0.050 (0.015) 0.025 (0.011),c
33) 0.033 (0.026) 0.038 (0.013) 0.040 (0.020)
14) 0.030 (0.018) 0.024 (0.013) 0.033 (0.010)
38) 0.030 (0.011)
,b 0.058 (0.022) 0.033 (0.013),c
18) 0.013 (0.007) 0.017 (0.013) 0.017 (0.010)
on the same day (P< 0.05) (Mann-Whitney U test). AC¼ acylcarnitines;
www.jpgn.org
Cosigned rank tests were performed. The level of statistical signifi-
cance was set at P< 0.05 for all tests.
RESULTS
The plasma levels of FC and different ACs are summarized
in Table 1. Virtually no statistically significant difference was
observed in the levels of either FC or individual esters in the human
milk fed (HM) infants when comparing the results obtained at days
0, 14 and 28. Contrarily, the amounts of total short-chain (SCAC),
total medium-chain, total long-chain (LCAC), and finally total ACs
(TAC) displayed alterations.
In the preterm formula-fed infants (IF) we did not detect any
differences in FC and AC according to the subgroups receiving
different docosahexaenoic acid intakes; therefore, results for all IF
infants are grouped together. At day 14, a marked increase in FC
along with significantly elevated C2 and C3 esters, total short-chain
esters, and total esters was found, as compared with the results of
day 0. Furthermore, the amount of some medium-chain (C8:1, C12)
and long-chain esters (C14, C16) decreased significantly. The levels
of FC and C2 and C3 esters increased further to day 28, which
resulted in the significant elevation of the total short-chain and
finally the total AC and total carnitine (TC) levels at day 28 com-
pared to the results of day 0. Simultaneously, the values of C8:1,
C12, C14, and C16 remained decreased at day 28.
Comparison of the results of HM-fed and IF-fed groups
revealed significant differences in the concentrations of FC and
different ACs between the 2 groups during the study period. At
baseline (day 0), there was no significant difference in the levels of
FC and individual ACs between the 2 study groups; however,
14 days later, marked changes were observed. The levels of FC
(Fig. 1) and all of the short-chain esters were found to be markedly
higher in the IF group than in the HM group (by 20%–70% of the
day 14 values of HM); moreover, the amounts of C8 and C10 were
also found to be significantly higher (by 39% and 16% of the day
14 value of HM, respectively). In addition, the levels of C12, C14,
and C16 esters were considerably lower in the IF group than in the
HM group (by 50% of the day 14 values of HM). There were no
statistically significant differences in the levels of other ACs
between the 2 study groups.
At day 28, there was no substantial further change in the
JPGN  Volume 57, Number 5, November 2013pyright 2013 by ESPGHAN and NASPGHAN. Un
carnitine ester pattern between the 2 study groups when comparing




























FIGURE 1. Plasma-free carnitine (C0), total acylcarnitine (TAC), and total
milk (HM) and with preterm infant formula (IF) in days 0, 14, and 28.
www.jpgn.orgdifferent ACs resulted in a significantly higher levels of total
SCACs, total ACs (Fig. 1). and lower levels of total LCACs in
the IF group compared with the HM group. In spite of the lower
levels of LCAC, the levels of TC are still higher in the IF group than
in the HM group (Fig. 1).
DISCUSSION
Carnitine has been considered as a conditionally essential
nutrient for human adults, children, neonates, and, especially,
premature infants. Neonates have a reduced ability to synthesize
carnitine, and premature neonates have reduced tissue stores
because they lack the major portion of placental carnitine transfer,
which takes places during the third trimester; hence, they largely
rely on exogenous carnitine after birth (11). During the past few
decades, a large number of publications established physiological
functions of carnitine and revealed its relevance in normal and
pathological conditions (15–19); however, the methodology used
earlier was based on the radioenzymatic determination of carnitine.
Using alkaline hydrolysis, only the determination of F and TC levels
and calculation of the amount of the TC esters was possible without
any information of the composition of the acyl groups. The intro-
duction of MS has enabled sensitive measurements of specific
carnitine esters. Despite the introduction of this tool into the new-
born screening program for inborn errors of metabolism (20),
studies on carnitine ester evolution in neonates are scarce (21,22).
In this study, we examined markers of carnitine metabolism
longitudinally during 4 weeks in preterm infants HM or IF. During
the 1-month follow-up, no substantial changes were observed in the
HM fed group. Our present data suggest that feeding HM leads to
development of a steady state condition in the plasma carnitine
levels regardless of the weight gain and increasing human milk
intake during this period of time.
Although the infant formula used in this study contains about
twice as much FC as found in human milk (approximately 40–50
mmol/L (23)), remarkable alterations were observed in the carnitine
ester profile between the 2 study groups. Similarly to Shortland et al
(24), we detected a higher amount of FC, TC, and TACs at day 28 in
the IF group. In addition, we also detected changes of individual
acyl carnitines. Besides the increased levels of SCACs and few
medium-chain ACs that may result from the higher medium-chain
Carnitine Ester Profile in Preterm Infantsauthorized reproduction of this article is prohibited.
triglycerides content of the preterm IF, we also observed lower
amounts of LCACs in the IF than in the HM group.




carnitine (TC) concentrations in preterm infants feeding with human
675
CoOur results differ from those of Campoy et al (25), who found
lower levels of total SCAC, TAC, TC, and higher levels of LCAC in
the late neonatal period in full-term infants fed cow’s-milk formula
compared with breast-fed infants. In contrast, we found higher
amounts of total SCAC and lower levels of total LCAC in the IF
than in the HM group. A possible reason for these differences may
be different methods used to determine carnitine esters. Until now
only 1 study was published in which the AC profiles of the preterm
neonates were assessed by MS. In this study, Meyburg et al
determined longitudinal changes in AC profiles of full-term and
preterm neonates with different gestational ages (22); however, the
concept of their study differed from ours and hence results are
not comparable.
Our results show that formula feeding of preterm infants is
metabolically not equivalent to breast-feeding. The protein, amino
acid, and fatty acid composition of preterm formula differs from
HM; therefore, bulk elimination, metabolism, and detoxification
differ. Our data demonstrate the involvement of carnitine metab-
olism in these processes. Carnitine probably plays an important
dynamic role in these complex metabolic events that affects a large
number of metabolites. Because the short- and long-term con-
sequences of such metabolic alterations are unknown, it would
appear prudent to try to approach the metabolic response of breast-
fed infants as much as feasible also in infants fed formula.
Acknowledgment: Preterm infant formula for this trial was
supplied by Nestlé Nutrition, Frankfurt, Germany.
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